A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis

Cancer Discovery

Volumn 7, Issue 7, 2017, Pages 694-703

  Ajona, Daniel ^a,b,c,d   Ortiz Espinosa, Sergio ^a,d   Moreno, Haritz ^a,b   Lozano, Teresa ^a,b   Pajares, María J ^a,b,c,e   Agorreta, Jackeline ^a,b,c,e   Bértolo, Cristina ^a   Lasarte, Juan J ^a,b   Vicent, Silvestre ^a,b,e   Hoehlig, Kai ^f   Vater, Axel ^f   Lecanda, Fernando ^a,b,c,e   Montuenga, Luis M ^a,b,c,e   Pio, Ruben ^a,b,c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f Aptarion Biotech   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CD8 ANTIGEN; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PEPTIDE APTAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; LUNG TUMOR; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; APTAMERS, PEPTIDE; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMPLEMENT C5A; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 85022006257     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-1184     Document Type: Article

References (25)

1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35.
2. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immuno-therapies to combat cancer. Nat Rev Cancer 2015;15:457–72.
3. Youn J-I, Nagaraj S, CollazoM, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791–802.
4. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41:2977–86.
5. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674–83.
6. Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev 2016;274:290–306.
7. Pio R, Ajona D, Lambris JD. Complement inhibition in cancer therapy. Semin Immunol 2013;25:54–64.
8. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225–35.
9. Sharma SK, Chintala NK, Vadrevu SK, Patel J, Karbowniczek M, Markiewski MM. Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol 2015;194:5529–38.
10. Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement C5a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche. Cancer Res 2014;74:3454–65.
11. Wang Y, Sun S-N, Liu Q, Yu Y-Y, Guo J, Wang K, et al. Autocrine complement inhibits IL10-dependent T-cell mediated antitumor immunity to promote tumor progression. Cancer Discov 2016;6: 1022–35.
12. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23:2140–51.
13. Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol 2014;772:229–62.
14. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180–90.
15. Janelle V, Langlois M-P, Tarrab E, Lapierre P, Poliquin L, Lamarre A. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res 2014;2:200–6.
16. Kim AHJ, Dimitriou ID, Holland MCH, Mastellos D, Mueller YM, Altman JD, et al. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol 2004; 173:2524–9.
17. An L-L, Gorman J V, Stephens G, Swerdlow B, Warrener P, Bonnell J, et al. Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep 2016;6:33346.
18. Ward PA, Guo R-F, Riedemann NC. Manipulation of the complement system for benefit in sepsis. Crit Care Res Pract 2012;2012: 427607.
19. Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A. Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun 2015;6: 6481.
20. Hoehlig K, Maasch C, Shushakova N, Buchner K, Huber-Lang M, Purschke WG, et al. A novel C5a-neutralizing mirror-image (L-) aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther 2013;21:2236–46.
21. Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis 2015;60:586–95.
22. Jayne DR, Bruchfeld A, Schaier M, Ciechanowski K, Harper L, Jadoul M, et al. OP0227 oral C5a receptor antagonist CCX168 phase 2 clinical trial in ANCA-associated renal vasculitis. Ann Reum Dis 2014;73:148.
23. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(®) therapeutics. Drug Discov Today 2015;20:147–55.
24. Bleau A-M, Freire J, Pajares MJ, Zudaire I, Anton I, Nistal-Villán E, et al. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations. Int J Cancer 2014;135:2516–27.
25. Antón I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, et al. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 2012;186:96–105.